In the immune-high group, HR + HER2− breast cancer contained the best prognosis (C3) and worse prognosis (C6) tumors supporting that there are differences between immune-high TN and HER2 + HER2− tumors that may explain why they have differential prognosis and response to ICI. This evidence concerns the gene ERBB2 and breast carcinoma.